LifeMD GLP-1 safety claims and Iowa's PBM

Two stories that ran on the same day in July 2026 point to different pressure points in the GLP-1 supply chain: one about clinical speed at a telehealth company, and one about money quietly moving between a pharmacy benefit manager and the state of Iowa. Neither story is about the drugs themselves. Both stories are about the infrastructure around them.

What former LifeMD workers say

LifeMD is a U.S. telehealth platform listed by Novo Nordisk as a provider offering "legitimate medicine sourcing and patient support" for GLP-1 drugs including Wegovy^[1]. The company serves more than 745,000 patients and prescribes branded GLP-1 medications such as semaglutide (Wegovy) and tirzepatide (Zepbound) through online consultations^[2].

According to reporting by Ed Silverman in STAT News on 20 July 2026, some former LifeMD employees say the company sought to maximise prescription volume at the expense of patient safety^[1]. Two former workers said providers were expected to review approximately 25 patient cases per hour. At that pace, each review runs to roughly two minutes. The evaluations were based on electronic forms completed by patients rather than live clinical exchanges.

LifeMD has not publicly responded to the specific allegations in the STAT report. The company's public-facing materials describe access to board-certified providers and same-day prescriptions^[2].

Why two minutes per case matters

GLP-1 receptor agonists are not without contraindications. Semaglutide and tirzepatide both carry boxed warnings about medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Both are contraindicated in patients with a personal or family history of those conditions. A review limited to a patient-completed form may miss the history needed to screen for those risks, as well as drug interactions, existing cardiovascular conditions, and relevant gastrointestinal history that affects tolerability and dosing.

The concern is not theoretical. The FDA has issued warning letters to telehealth platforms over the past two years for prescribing compounded semaglutide without adequate safety screening. The specific allegations against LifeMD concern branded prescriptions, not compounded ones, but the underlying question about clinical depth applies across both categories.

The Iowa Medicaid PBM audit

The second story in the same STAT Pharmalittle column covers an audit of Iowa Medicaid pharmacy benefit manager records from 2019 to 2021^[1]. Auditors found that one large PBM used what they described as "complicated and sophisticated approaches" to handle prescription drug claims in ways that resulted in taxpayer overcharges.

The mechanism: the PBM adjusted payments to pharmacies but did not return all resulting savings to the managed-care plans that represent the state. According to the audit, the value of those retained adjustments appeared to exceed $100 million over the review period. The audit does not name the PBM publicly in the summary reporting available, but Iowa Medicaid contracts with national pharmacy benefit managers as part of its managed-care structure.

PBMs and how they sit in the drug supply chain

Pharmacy benefit managers sit between insurers, employers, and pharmacies. They negotiate drug prices with manufacturers, set the formulary lists that determine which drugs get covered, and process the claims that flow from dispensing pharmacies back to payers. The three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, handle the majority of U.S. prescription drug transactions. Because their revenue model involves capturing a portion of the spread between what they pay pharmacies and what they bill payers, auditors have long questioned whether their financial incentives align with the payers they serve.

For GLP-1 drugs specifically, formulary placement decisions made by PBMs have direct effects on which medications patients can access at what cost. CVS Caremark's decision to restore coverage for tirzepatide (Zepbound) in 2026 after excluding it in favour of semaglutide the prior year is one example of how PBM decisions reshape access at scale. The Iowa audit is a reminder that PBM decisions affecting state Medicaid programmes carry fiscal consequences that auditors can and do examine retroactively.

What these two stories have in common

The LifeMD allegations and the Iowa Medicaid audit are not connected. One involves a telehealth company's clinical workflow; the other involves a PBM's financial workflow. But they land on the same day for a reason: the GLP-1 market is large enough, and growing fast enough, that the institutional scaffolding around prescribing and reimbursement is drawing regulatory and journalistic attention it may not have received when volumes were lower.

Patients seeking GLP-1 prescriptions through telehealth should understand that the prescribing encounter, however brief it appears on the platform, is a medical evaluation with real stakes. If you have a personal or family history of medullary thyroid carcinoma, MEN-2, pancreatitis, or relevant gastrointestinal conditions, that history needs to reach your prescriber. A two-minute asynchronous form review is not a substitute for a complete clinical picture. If you are unsure whether your telehealth consultation covered that ground, ask directly or consult a clinician who can review your full medical history before you start or continue treatment.

This article covers reporting about telehealth prescribing practices and pharmacy benefit manager audits. It is not medical advice. Speak with a qualified healthcare provider before starting, adjusting, or stopping any medication.